Core Insights - The research team at the Tianjin Institute of Industrial Biotechnology has made significant advancements in the field of cellulose-to-starch conversion, achieving a theoretical starch yield increase from 50% to 100% through innovative energy cycle reconstruction and enzyme stability improvements [1][2]. Group 1: Research Achievements - The team has successfully restructured the synthetic pathway for cellulose utilization, addressing the carbon loss issue and enhancing the theoretical yield of starch [1]. - By innovating glucose recovery and activation mechanisms, the team has fundamentally improved the efficiency of the conversion process [1]. - The actual conversion rate from cellulose to starch has been raised to 93.3% through systematic optimization of various factors in the reaction system [1]. Group 2: Product Characteristics and Applications - The starch produced is pure linear starch with highly controllable polymerization degrees, narrow molecular weight distribution, and superior structural uniformity compared to naturally extracted starch [2]. - This new starch has unique application potential in food, pharmaceuticals, and materials, having already been successfully applied in chiral separation fillers for efficient separation of chiral drug molecules [2].

Group 1: Company Overview - Moer Thread is a leading company in the domestic GPU sector, recognized for its full-function GPU R&D capabilities, and will become the "first domestic GPU stock" upon listing [1][2] - The company has successfully launched four generations of GPU architecture, covering various application fields including AI computing, high-performance computing, and graphics rendering [2] - Baiaosaitu is a preclinical CRO and biotechnology company that provides innovative animal models and preclinical drug development services based on its proprietary gene editing technology [3][4] Group 2: Financial Performance - Moer Thread's projected revenues for 2022, 2023, and 2024 are 0.46 billion, 1.24 billion, and 4.38 billion respectively, with net losses of -1.894 billion, -1.703 billion, and -1.618 billion [2] - Baiaosaitu's projected revenues for the same years are 0.534 billion, 0.717 billion, and 0.98 billion, with net losses of -0.602 billion, -0.383 billion, and a profit of 0.034 billion in 2024 [4] Group 3: Fundraising and Investment Plans - Moer Thread plans to use the funds raised for the development of next-generation AI training and inference chips, graphics chips, and AISoC chips, as well as to supplement working capital [2] - Baiaosaitu intends to invest the raised funds in early-stage drug development service platform construction, antibody drug R&D and evaluation projects, and preclinical R&D projects [4]

根据发行安排，本周（11月24日—11月28日），A股市场将有两只新股申购，为科创板的摩尔线程和百奥赛图， 两股分别将于本周一和周五开启申购。 资料显示，摩尔线程是国内GPU领域龙头，公司是国内极少数具备全功能GPU研发能力的企业，上市后公司将 成为"国产GPU第一股"。百奥赛图是全球领先的创新技术驱动型生物技术公司。 依托于抗体药物发现平台的领先优势，公司通过RenMice小鼠授权以及"千鼠万抗"的形式展开抗体对外合作开 发。目前公司已与Merck KGaA（德国默克）、Gilead Sciences（吉利德科学）、Johnson&Johnson（强生公 司）、IDEAYA Biosciences、Neurocrine Biosciences、百济神州、Xencor、ADC Therapeutics、Myricx Bio、 ABL Bio、翰森制药、正大天晴、华润生物、信达生物、荣昌生物、上海生物制品研究所等数十家海内外知名 生物科技或医药研发企业就"千鼠万抗"发现的药物分子授权/转让或RenMice平台授权达成合作。 2022—2024年，公司实现营业收入分别为5.34亿元、7.17亿元、9.8亿元，归属 ...

Group 1: New Stock Offerings - Two new stocks will be available for subscription on the Sci-Tech Innovation Board next week: Moer Thread on November 24 and Bai Ao Sai Tu on November 28 [1] - Moer Thread's offering price is set at 114.28 yuan per share, making it the highest IPO price this year, with a total fundraising target of 8 billion yuan [1][2] - Moer Thread is expected to become the "first domestic GPU stock" upon listing, with a total market capitalization projected to reach 53.7 billion yuan [2] Group 2: Moer Thread Company Overview - Moer Thread focuses on the research, design, and sales of GPUs and related products, aiming to provide computing acceleration platforms for high-performance computing fields such as AI and digital twins [2] - The company has launched four generations of GPU architectures since its establishment in 2020, but has not yet achieved profitability, reporting losses from 2022 to 2025 [2] Group 3: Bai Ao Sai Tu Company Overview - Bai Ao Sai Tu is a leading company in the field of model animals, focusing on preclinical research and biotechnology services [3] - The company utilizes its proprietary gene editing technology to provide innovative model animals and drug development services, and has been listed in Hong Kong since 2022 [3] - Bai Ao Sai Tu has shown revenue growth from 5.34 billion yuan in 2022 to an expected 9.80 billion yuan in 2024, with a net profit turning positive in 2025 [3]

(1)公司是否存在股权代持，包括历史沿革及现有股东间接持有发行人的股份中是否存在股权代持情 形，不限于直接持股股东； (2)发行人顾问邵文姬配偶的基本信息及顾问合同期限； (3)公司员工持股计划包括少量外部人员，请补充说明相关人员的入股价格、作价依据、价格公允性、 资金来源，如入股价格与员工相同或相近，应当说明是否存在利益输送，并出具明确的结论性意见。 11月21日，中国证监会公布境外发行上市备案补充材料要求公示(2025年11月17日—2025年11月21日)。 证监会要求麦科奥特补充说明历次增资及股权转让价格、定价依据及公允性，是否实缴出资，是否存在 未履行出资义务、抽逃出资、出资方式存在瑕疵的情形；就公司设立及历次股权变动是否合法合规进行 核查，并出具结论性意见。据港交所9月29日披露，麦科奥特向港交所提交上市申请书，建银国际、招 商证券国际为其联席保荐人。该公司有望成为多肽创新药第一股。 同时，证监会要求公司补充说明以下事项，请律师核查并出具明确的法律意见： 按照《监管规则适用指引——境外发行上市类第2号》补充说明公司控股股东及主要股东上层投资人西 安众瑞泽康企业管理咨询有限公司、Nexarcana ...

Core Viewpoint - Public QDII funds are leveraging their positions in the US stock market to enhance net value defense and differentiate their product offerings amidst the recent pullback in the Hong Kong stock market [1][2]. Group 1: Performance of QDII Funds - Despite an overall decline in net value for public QDII funds in recent months, those with a focus on US stocks have shown strong performance, ranking among the top in net value gains during market adjustments [2][4]. - Notable QDII funds such as CICC Global Healthcare and E Fund Global Growth Select have reported significant gains of 11.78% and 7.22% respectively over the past month, making them some of the few active equity QDIIs to achieve positive returns [2]. Group 2: Stock Selection and Market Strategy - Core stocks from the US market have bolstered the net value defense of these funds, with examples like Cidara, which saw a 105% increase in a single day due to a major acquisition announcement [3]. - The strategy of reallocating from Hong Kong stocks to US stocks has been evident, with some funds increasing their US stock positions significantly, such as CICC Global Healthcare, which shifted from 3% to 71% in US stocks within a quarter [6]. Group 3: Differentiation and Market Trends - The trend of increasing US stock positions among public QDIIs has been apparent since the end of Q3, as funds seek to distinguish themselves in a competitive market [4][5]. - The E Fund Asia Select QDII, managed by a prominent fund manager, has benefited from a 40% annual return, attributed to a 32.24% allocation in US stocks, significantly higher than earlier in the year [5]. Group 4: Impact of AI and Technology - The demand for computing power driven by AI technology has significantly enhanced the attractiveness of US QDIIs, with fund managers optimistic about the long-term investment value in leading tech companies [7][8]. - The rapid growth in AI applications has led to increased expectations for the scale of computing infrastructure, with funds like Jianxin Emerging Markets QDII holding 50% in US stocks, reflecting a strategic focus on this sector [8].

Core Viewpoint - The article highlights the importance of supporting rural children's growth and education, showcasing the "Youyi New Bud" Sunshine Care Program by Jiabiou Biotechnology, which aims to provide safety and support for students in rural areas [1][2]. Group 1: Company Initiatives - Jiabiou Biotechnology has launched the "Youyi New Bud" Sunshine Care Program, collaborating with various partners to provide tailored safety uniforms and winter pants to 189 students at a primary school in Laifeng County [1][2]. - The program follows a mature public welfare model of "material donation + knowledge transfer," emphasizing both material support and educational empowerment for rural children [1][2]. Group 2: Community Impact - The donated "Siyuan Ark" safety uniforms are designed with reflective strips to enhance visibility in low-light conditions, increasing the distance at which drivers can see students to over 150 meters [2]. - The initiative reflects a collaborative effort among local organizations, including the Laifeng County Golden Sun Public Welfare Association, to innovate public welfare models and support rural education [2][3]. Group 3: Future Directions - Laifeng County plans to continue fostering public welfare cooperation platforms to channel quality resources into rural education and child care [3]. - Jiabiou Biotechnology aims to deepen its commitment to public welfare while maintaining its focus on its core biotechnology business, demonstrating corporate social responsibility [3].

Summary of RenovoRx Conference Call (November 20, 2025) Company Overview - **Company**: RenovoRx (NasdaqCM:RNXT) - **Market Cap**: Approximately $30 million - **Focus**: Interventional oncology with a late-stage product in development and a commercial catheter device - **Current Stock Price**: Approximately $0.75 - **Analyst Rating**: Buy rating with a price target of $3 per share [1][17] Core Business and Product Development - **Product**: RenovoCath, a catheter device for localized chemotherapy - **Revenue**: Achieved $900,000 in revenue through Q3 2025 without a dedicated sales and marketing team [3][13] - **Market Potential**: Estimated peak sales potential for the catheter is about $400 million [3][8] - **Commercialization Strategy**: Initiated in early 2025, focusing on understanding market dynamics and barriers to adoption [3][9] Technology and Treatment Approach - **Innovative System**: Developed a new treatment method called TransArterial Microperfusion (TAMP) for localized chemotherapy [2][5] - **Mechanism of Action**: Allows for a hundred-fold increase in tissue concentration of chemotherapy compared to systemic delivery [7][8] - **Targeted Conditions**: Primarily focused on locally advanced pancreatic cancer, with ongoing phase III trials [4][10] Clinical Trials and Efficacy - **Phase III Trial**: Enrollment expected to complete early next year, with final data anticipated in 2027 [4][14] - **Survival Benefits**: Interim analysis shows a six-month survival benefit, with patients living approximately 21.5 months compared to 15.5 months in the control group [10][40] - **Quality of Life**: Notable 65% reduction in systemic toxicities and adverse events compared to traditional therapies [11][40] Market Dynamics and Sales Strategy - **Target Market**: Approximately 200 hospitals in the U.S. with specialized cancer centers [9] - **Sales Force**: Currently expanding with the hiring of a Senior Director of Sales and Marketing, along with additional sales representatives [9][20] - **Revenue Model**: Each patient may require multiple procedures, potentially generating $50,000 to $100,000 in revenue per patient [19][22] Financial Overview - **Cash Position**: $10 million in cash as of Q3 2025, with a monthly burn rate of $800,000 [16][44] - **Profitability Outlook**: Positive contribution margin on the device, with a goal to reach break-even with 25-50 hospitals actively using the device [22][23] Future Prospects and Strategic Initiatives - **Post-Marketing Registry Study**: Launched to track data on the use of RenovoCath across various cancers [12][13] - **Expansion Plans**: Exploring additional indications and potential partnerships with other biotech firms for drug-device combinations [42][43] - **Regulatory Strategy**: Aiming for a J-code drug reimbursement for the drug-device combination, which could significantly increase market potential [17] Key Takeaways - RenovoRx is positioned to disrupt traditional cancer treatment paradigms with its innovative localized chemotherapy approach - The company is on track to expand its market presence and revenue generation capabilities through strategic hiring and commercialization efforts - Clinical trial results and a strong focus on quality of life improvements are expected to drive adoption among oncologists and patients alike [10][11][40]

CytomX Therapeutics Conference Call Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Focus**: Therapeutic antibody company specializing in oncology - **Technology**: ProBody Therapeutic Platform, a masking strategy to enhance therapeutic windows for various antibody modalities in oncology, including antibody-drug conjugates (ADCs), T-cell engagers, and cytokines [3][4][7] Key Developments in 2025 - **Clinical Programs**: - **CX-2051**: A masked antibody-drug conjugate targeting EpCAM, with promising phase one data presented in May 2025, showing a confirmed overall response rate of 28% in late-stage colorectal cancer (CRC) patients [10][11] - **Interferon Alpha**: A second clinical program with recent data presented at CITSI [4] - **Market Conditions**: Improvement in capital markets has positively impacted the company [5] Clinical Data Highlights - **CX-2051 Phase One Study**: - **Patient Population**: Late-stage CRC patients (median of four prior therapies) [24] - **Efficacy**: - Overall response rate of 28% across three dose levels (7.2, 8.6, and 10 mg/kg) [10] - Progression-free survival (PFS) of 5.8 months, compared to 3-3.5 months for current standard of care [29] - Disease control rate of 94% [11] - **Safety Profile**: Well tolerated with low rates of hematologic toxicity; however, 21% grade three diarrhea reported [33] Technology Differentiation - **Masking Technology**: The ProBody Therapeutic approach allows for selective binding to tumor tissues while minimizing binding to normal tissues, enhancing the therapeutic window [7][10] - **Target Selection**: EpCAM is highly expressed in CRC, making it a viable target for systemic therapy [9][25] - **Payload Mechanism**: The use of a topoisomerase I inhibitor (CAMP59) linked to the antibody is crucial for efficacy in CRC [9][16] Future Expectations - **Enrollment Expansion**: Increased patient enrollment from 70 to approximately 100 patients to confirm efficacy and safety profiles, with data disclosure expected in Q1 2026 [20][22] - **Regulatory Path**: Aiming for a registrational study in 2026 based on robust phase one data [42] Financial Position - **Cash Reserves**: Approximately $150 million, funding operations into Q2 2027 [44] - **Partnerships**: Ongoing collaborations with Regeneron and Astellas, with active business development efforts [44] Conclusion CytomX Therapeutics is positioned for significant advancements in the oncology space with its innovative masking technology and promising clinical data for CX-2051. The company is well-funded and actively pursuing regulatory pathways to bring its therapies to market, particularly in the challenging area of late-stage colorectal cancer treatment.

Core Insights - The article discusses the significance of hydrogen bonds in stabilizing protein structures, particularly in β-sheet layers, which allow proteins to withstand mechanical and environmental stress [3][6] - A research team led by Professor Zheng Peng from Nanjing University has developed a new computational design method for superstable proteins, utilizing AI, molecular dynamics simulations, and single-molecule force spectroscopy [4][10] Group 1: Research Findings - The research successfully designed a protein named "SuperMyo" that exhibits mechanical properties significantly superior to natural proteins, with a mechanical unfolding force exceeding 1000 piconewtons, which is over five times that of natural immunoglobulin domains [8] - The number of backbone hydrogen bonds in the designed proteins was increased from 4 to 33, maximizing the hydrogen bonding network and enabling tailored mechanical performance [6][8] - "SuperMyo" also demonstrates exceptional thermal stability, with a melting temperature exceeding 100°C, maintaining structural integrity even at extreme temperatures of 150°C [8] Group 2: Implications and Applications - The molecular-level stability of "SuperMyo" translates into macro properties, as hydrogels made from this protein can retain their structure and gel state after high-pressure sterilization at 121°C, unlike traditional protein hydrogels that denature under such conditions [8] - This research presents a scalable and efficient computational design strategy for creating robust proteins, providing a general method for rationally designing proteins that can withstand extreme environments [10]